Guardant Health Inc (GH)

Sep 21, 2026

Guardant Health, Inc. (GH) is positioned as a strong buy in the diagnostics and research industry, specializing in cancer diagnostics with a market capitalization of $24.07 billion. Despite a lack of traditional P/E ratios, the company's impressive revenue growth of 44.30% and positive analyst sentiment with a 9.16% upside potential highlight its robust growth trajectory. Guardant Health's strategic reinvestment in R&D and diverse portfolio of tests like Guardant360 CDx underscore its commitment to advancing personalized medicine and cancer treatment.

Sep 15, 2026

Patrick Dempsey is spearheading Guardant Health's new multi-million dollar "The Reckoning" campaign, urging early colorectal cancer screening with Guardant's Shield™ blood test. The campaign highlights the rising death toll from colorectal cancer, particularly among younger adults, and promotes Shield™ as the first FDA-approved primary blood test for screening. Dempsey, a long-time cancer advocate, aims to reduce screening barriers and honor those affected by the disease.